Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ecopipam DDI Study in Healthy Subjects
NCT05334108Phase 1Completed
- Sponsor
- Emalex Biosciences
- Start
- Apr 2022
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ecopipam in Tourette syndrome (TS) and childhood-onset fluency disorder (COFD) (3 cohorts), sponsored by Emalex Biosciences. Primary endpoints: Maximum Plasma Concentration (Cmax) of IV midazolam (and metabolite) in the presence of ecopipam, Maximum Plasma Concentration (Cmax) of IV midazolam (and metabolite) in the absence of ecopipam and 44 more. Started Apr 2022; status: completed.
02
Drugs
ecopipam
03
Conditions
Tourette syndrome (TS)childhood-onset fluency disorder (COFD)
Beyond the preview
Go deeper on NCT05334108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05334108.